The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors

British Journal of Pharmacology

Volumn 144, Issue 3, 2005, Pages 317-322

  Baker, Jillian G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adrenoceptor; agonist; antagonist; blocker; Drug selectivity; Whole cell binding

Indexed keywords

1 (2 CYANOPHENOXY) 3 [2 (3 PHENYLUREIDO)ETHYLAMINO] 2 PROPANOL; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARVEDILOL; LIGAND; METOPROLOL; PRACTOLOL; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; XAMOTEROL;

ANIMAL CELL; ARTICLE; ASTHMA; BINDING AFFINITY; CHO CELL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BINDING; DRUG SELECTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHOLE CELL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; DIOXOLES; HUMANS; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3;

EID: 14644421602     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706048     Document Type: Article

References (27)

1. AZZI, M., CHAREST, P.G., ANGERS, S., ROSSEAU, G., KOHOUT, T., BOUVIER, M. & PINERYO, G. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A., 100, 11406-11411.
2. AZZI, M., PINERYO, G., PONTIER, S., PARENT, S., ANSANAY, H. & BOUVIER, M. (2001). Allosteric effects of G protein overexpression on the binding of β-adrenergic ligands with distinct inverse effacacies. Mol. Pharmacol., 60, 999-1007.
3. 2-adrenoceptor. Br. J. Pharmacol., 137, 400-408.
4. BAKER, J.G., HALL, I.P. & HILL, S.J. (2003a). Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol. Pharmacol., 64, 679-688.
5. 1-adrenoceptor. Mol. Pharmacol., 63, 1312-1321.
6. BAKER, J.G., HALL, I.P. & HILL, S.J. (2003c). Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol. Pharmacol., 64, 1357-1369.
7. BETA-BLOCKER EVALUATION OF SURVIVAL TRIAL INVESTIGATORS (BEST) (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med., 344, 1659-1667.
8. BLACK, J.W., DUNCAN, W.A.M. & SHANKS, R.G. (1965). Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol., 25, 577-591.
9. 2-adrenoceptor. Nature, 374, 272-276.
10. CHIDIAC, P., HEBERT, T.E., VALIQUETTE, M., DENNIS, M. & BOUVIER, M. (1994). Inverse agonist activity of β-adrenergic antagonists. Mol. Pharmacol., 45, 490-499.
11. CIBIS-II (1999). Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 353, 9-13.
12. COMET:POOLE-WILSON, P.A., SWEDBERG, K., CLELAND, J.G., DI LENARDA, A., HANRATH, P., KOMAJDA, M., LUBSEN, J., LUTIGER, B., METRA, M., REMME, W.J., TORP-PEDERSEN, C., SCHERHAG, A, SKENE, A. & CARVEDILOL OR METOPROLOL EUROPEAN TRIAL INVESTIGATORS. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362, 7-13.
13. FEELY, J. & PEDEN, N. (1984). Use of beta-adrenoceptor blocking drugs in hyperthyroidism. Drugs, 27, 425-446.
14. HARMS, H.H. (1976). Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J. Pharmacol. Exp. Ther., 199, 329-335.
15. HEIDENREICH, P.A., MCDONALD, K.M., HASTIE, T., FADEL, B., HAGAN, V., LEE, B.K. & HLATKY, M.A. (1999). Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. J. Am. Medic. Assoc., 281, 1927-1936.
16. HOFFMANN, C., LEITZ, M.R., OBERDORF-MAASS, S., LOHSE, M.J. & KLOTZ, K.N. (2004). Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptor in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 151-159.
17. JASPER, J.R., MICHEL, M.C. & INSEL, P.A. (1990). Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists. Mol. Pharmacol., 37, 44-49.
18. KOBILKA, B. (1992). Adrenergic receptors as models for G protein-coupled receptor. Annu. Rev. Neurosci., 15, 87-114.
19. LEWIS, R.V. & LOFTHOUSE, C. (1993). Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf., 9, 272-279.
20. LIANG, W. & MILLS, S. (2001). Profile of ligand binding to the porcine β2-adrenergic receptor. J. Anim. Sci., 79, 877-883.
21. LIMMROTH, V. & MICHEL, M.C. (2001). The prevention of migraine: a critical review with special emphasis of β-adrenergic blockers. Br. J. Clin. Pharmacol., 52, 237-243.
22. PEET, M. & YATES, R.A. (1981). Beta-blockers in the treatment of neurological and psychiatric disorders. J. Clin. Hosp. Pharm., 6, 155-171.
23. PRICHARD, B.N. (1988). Beta-blockade therapy and cardiovascular disease. Past, present and future. Postgrad. Med., 29, 8-18.
24. PRICHARD, B.N., CRUICKSHANK, J.M. & GRAHAM, B.R. (2001). Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press., 10, 366-386.
25. SMITH, C. & TEITLER, M. (1999). Beta-blocker selectivity at cloned human beta1- and beta2-adrenoceptors. Cardiovasc. Drugs Ther., 13, 123-126.
26. STAMPER, R.L., WIGGINGTON, S.A. & HIGGINBOTHAM, E.J. (2002). Primary drug treatment for glaucoma: beta-blocker versus other medications. Surv. Ophthalmol., 47, 63-67.
27. UITTI, R.J. (1998). Medical treatment of essential tremor and Parkinson's disease. Geriatrics, 53, 46-48, 53-57.